When global pharmaceutical companies or health sector enterprises search for a Chinese biological products factory, one name consistently stands out: Kexing Biopharm.

Biopharmaceuticals, also known as biologics, have redefined the landscape of modern medicine.

The biopharmaceutical industry is undergoing a transformative era, driven by cutting-edge research, technological advancements, and an increasing demand for novel therapies.

Synthetic biology is an emerging interdisciplinary field that integrates knowledge and techniques from biology, genomics, engineering, and informatics.

In the field of bioengineering, protein design has always been a challenging task. With the rapid development of artificial intelligence (AI) technology, especially the breakthroughs in deep learning algorithms, AI-driven protein design is sparking a revolution.

In recent years, China has been making significant strides in the field of biotechnology, positioning itself as a potential global leader in the export of biological products.

In the rapidly evolving landscape of pharmaceuticals, recombinant protein drugs have emerged as a cornerstone of modern healthcare.

In the quest for a sustainable future, the role of high-quality biological products cannot be overstated. These products, derived from living organisms or their byproducts, are revolutionizing industries and contributing significantly to environmental sustainability.